



## PreComb Therapeutics appoints Dr. Andrew Thomas as Strategic Advisor

Wädenswil, Switzerland, October 18<sup>th</sup>, 2018 - PreComb, the leader in 3D microtumor combinatorial drug discovery, is excited to announce the appointment of Dr. Andrew Thomas as a new member of the Strategic Advisory Board. Dr. Thomas brings a wealth of expertise from over 20 year of key positions in global Pharma companies and small molecule drug discovery and development.

Dr. Thomas has previously been Global Head of Medicinal Chemistry at Roche, being responsible for creating and developing an innovative portfolio of small molecule medicines for Neuroscience, Ophthalmology, Rare Diseases, Inflammation, Infectious Diseases, Immunology and Oncology. He is a founder and executive partner of IPSO group, Investment Director at Helvetica Capital and an active driver of the Swiss Entrepreneurs Foundation.

“We are proud to welcome Andrew in our Advisory Board.” said Jens Kelm, CEO of PreComb. “His wealth of pharma experience in drug discovery and development and his entrepreneurial thinking will add tremendous value to our company and our mission to deliver novel combination therapies for difficult to treat cancers.”

### About PreComb Therapeutics

PreComb Therapeutics AG is a swiss-based biotechnology company focusing on the development of novel combination therapies, primarily for the use in oncology and immuno-oncology. PreComb is developing a phenotypical drug development platform using 3D microtumor cultures to enable high-throughput 3D combinatorial drug screening. The platform shall deliver more efficient cancer therapies to substantially improve long-term prognosis and quality-of-life for patients.

For more Information about PreComb Therapeutics, please visit <https://www.precomb.com> or follow us on [LinkedIn](#).

### Media contact

PreComb Therapeutics AG  
Dr. Peter Steiner  
[info@precomb.com](mailto:info@precomb.com)